Transforming Discovery into Opportunity

UBC and CDRD Ventures Inc. collaborate to design irreversible neuraminidase inhibtors as potential best-in-class flu therapies

Researchers at The University of British Columbia have used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase that could have activity against flu strains resistant to marketed inhibitors of the target. The new molecules are being developed by CDRD Ventures Inc., the venture arm of The Centre for Drug Research and Development, a public-private partnership that commercializes discoveries from Canadian researchers.

Jon Jafari, Director of Business Development for CDRD Ventures Inc. commented, “There’s a potential for this product to be best in class, with the potential for oral availability”.  It is intended that preclinical proof-of-concept studies will be completed by the end of this year at which point CDRD Ventures Inc. will seek to partner or out-license the compounds.  Dr. Stephen Withers, Professor of Chemistry and Biochemistry at UBC and Principal Investigator of this research stated,”I would anticipate that this would be a prophylactic taken ahead of time if your family gets the flu or there’s a pandemic”, thus indicating that these novel lead compounds could be used to stop the spread of flu as well as treating already infected individuals.

Click here to read the complete article.



Sign up to our newsletter

Receive CDRD's e-newsletter, The CDRD Pipeline and other e-communications for regular updates on all our news and activities.

© Copyright 2017 CDRD. All rights reserved.